Proniras Corporation Analysis: $11M Raised
What is Proniras Corporation?
Clinical-stage biotech targeting opioid withdrawal with tezampanel
HQ Country
Seattle, United States
Employees
1-10
Founded
2018
HQ State/Province
Washington
Funding Category
Series B
HQ Full Address
Seattle, Washington, United States
Product Features & Capabilities
- Tezampanel for opioid withdrawal treatment
- Clinical development of small-molecule therapeutics for CNS disorders
Other Considerations
Secured NIDA grant to support Phase 1 study; Raised Series B financing in 2024; Founded by Accelerator Life Science Partners; Based in Seattle, WA, US
